首页> 美国卫生研究院文献>other >Transcriptional Signatures Related to Glucose and Lipid Metabolism Predict Treatment Response to the Tumor Necrosis Factor Antagonist Infliximab in Patients with Treatment-Resistant Depression
【2h】

Transcriptional Signatures Related to Glucose and Lipid Metabolism Predict Treatment Response to the Tumor Necrosis Factor Antagonist Infliximab in Patients with Treatment-Resistant Depression

机译:与葡萄糖和脂质代谢相关的转录特征预测抗抑郁症患者对肿瘤坏死因子拮抗剂英夫利昔单抗的治疗反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The tumor necrosis factor (TNF) antagonist infliximab was recently found to reduce depressive symptoms in patients with increased baseline inflammation as reflected by a plasma C-reactive protein concentration >5mg/L. To further explore predictors and targets of response to infliximab, differential gene expression was examined in peripheral blood mononuclear cells from infliximab responders (n=13) versus non-responders (n=14) compared to placebo at baseline and 6hr, 24hr, and 2 weeks after the first infliximab infusion. Treatment response was defined as 50% reduction in depressive symptoms at any point during the 12-week trial. One-hundred-forty-eight gene transcripts were significantly associated (1.2 fold, adjusted p≤0.01) with response to infliximab and were distinct from placebo responders. Transcripts predictive of infliximab response were associated with gluconeogenesis and cholesterol transport, and were enriched in a network regulated by hepatocyte nuclear factor (HNF)4-alpha, a transcription factor involved in gluconeogenesis and cholesterol and lipid homeostasis. Of the 148 transcripts differentially expressed at baseline, 48% were significantly regulated over time in infliximab responders, including genes related to gluconeogenesis and the HNF4-alpha network, indicating that these predictive genes were responsive to infliximab. Responders also demonstrated inhibition of genes related to apoptosis through TNF signaling at 6hr and 24hr after infusion. Transcripts down-regulated in responders 2 weeks after infliximab were related to innate immune signaling and nuclear factor-kappa B. Thus, baseline transcriptional signatures reflective of alterations in glucose and lipid metabolism predicted antidepressant response to infliximab, and infliximab response involved regulation of metabolic genes and inhibition of genes related to innate immune activation.
机译:最近发现,肿瘤血浆坏死因子(TNF)拮抗剂英夫利昔单抗可减轻基线炎症增加的患者的抑郁症状,这可通过血浆C反应蛋白浓度> 5mg / L来反映。为了进一步探索对英夫利昔单抗的预测因素和靶标,在基线,6小时,24小时和2小时,与安慰剂相比,检查了英夫利昔单抗应答者(n = 13)与无应答者(n = 14)外周血单个核细胞中的差异基因表达首次英夫利昔单抗输注后数周。治疗反应定义为在12周的试验中任何时候抑郁症状减少50%。一百四十八个基因转录物与英夫利昔单抗反应显着相关(1.2倍,校正后的p≤0.01),与安慰剂反应者不同。预测英夫利昔单抗反应的转录物与糖原异生和胆固醇转运相关,并丰富了由肝细胞核因子(HNF)4-α(参与糖异生,胆固醇和脂质稳态的转录因子)调节的网络。在基线时差异表达的148个转录物中,英夫利昔单抗应答者中有48%随时间而受到显着调节,包括与糖异生相关的基因和HNF4-α网络,表明这些预测性基因对英夫利昔单抗有响应。应答者还显示了在输注后6小时和24小时通过TNF信号传导抑制与凋亡相关的基因。英夫利昔单抗2周后应答者下调的转录物与先天免疫信号和核因子-κB有关。因此,反映葡萄糖和脂质代谢变化的基线转录特征预示了对英夫利昔单抗的抗抑郁反应,英夫利昔单抗反应涉及代谢基因的调节。和抑制与先天免疫激活有关的基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号